Association of Hepatitis C Virus With Breast Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

650 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-01

Study Completion Date

2020-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatitis C viral infection is a major health problem in Egypt. The management of breast cancer patients is often complicated by the presence of associated HCV infection. This study aims at investigating the epidemiological association of the two conditions. It will also investigate the possible correlation with treatment outcome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metabolic Syndrome and Fatty Liver Disease Among Egyptian Patients with Chronic HBV

NCT06589167

Metabolic Syndrome Fatty Liver Disease

NOT_YET_RECRUITING

Metabolic Syndrome and Long-term Survival Following Liver Resection

NCT05568576

Survival

COMPLETED

The Relationship Between Fatty Liver and Breast Cancer

NCT06402084

The Relationship Between Fatty Liver and Breast Cancer

RECRUITING

Hepatic Steatosis and Chronic Hepatitis B Virus

NCT05678582

Chronic Hepatitis

COMPLETED

The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt

NCT05047146

Hepatocellular Carcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Breast cancer is the most common cancer in adult Egyptian females. The world's highest prevalence of hepatitis C virus is found in Egypt. Several investigators examined the epidemiological association of HCV with breast cancer. Published literature reports conflicting results regarding the HCV association with breast cancer incidence. Population-based studies from HCV-endemic area demonstrated increased breast cancer incidence in HCV-positive women younger than 50 years. On the other hand, population studies from HCV-low prevalence regions failed to detect an association of the virus with breast cancer.

HCV seropositive patients constitute a large sector of oncology patients treated in Egyptian practice. HCV infection with or without clinically-significant liver disease impose several therapeutic, social and logistic problems. Recently, investigators from Mansoura University reported their findings among breast cancerpatients. According to these data, HCV-positive breast cancer patients had several markers of disease aggression such as large tumor size, high tumor grade and nodal infiltration. Moreover, HCV-NS4 (non-structural protein-4) blood levels positively correlated with the level of the known breast cancer marker CA15-3.

In the current study, the investigators will investigate the incidence of HCV seropositivity in breast cancer patients and an age-matched control group. The study also examines the association of HCV status on the patients' baseline characteristics such as tumor stage and grade and with patients' treatment plan and treatment outcome.

Specifically, the aims of the study are the following:

1. To test if HCV seropositivity is associated with breast cancer diagnosis in Egyptian population.
2. To test if HCV-positive patients harbour more aggressive breast tumors.
3. To test if HCV-positivity affects management decision in breast cancer patients.
4. To test if HCV-positive patients suffer more frequent adverse effects to breast cancer treatment.
5. To compare disease-free survival of HCV seropositive breast cancer patients vs. seronegative patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.

No interventions assigned to this group

Control group

A group of age-matched women from the same geographical distribution who are healthy volunteers or hospital patients without cancer diagnosis will serve as a control group for the HCV prevalence. We aim at a sample size with a study-to-control ratio of 1:3.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Biopsy-proven invasive breast cancer.

Exclusion Criteria

* Patients with unknown viral marker status.
* Patients who did not complete their management at OCMU.
* Patients with multiple cancer diagnoses.
* Patients with virus-unrelated hepatic pathology.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes